US20060034812A1 - Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect - Google Patents
Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect Download PDFInfo
- Publication number
- US20060034812A1 US20060034812A1 US11/221,515 US22151505A US2006034812A1 US 20060034812 A1 US20060034812 A1 US 20060034812A1 US 22151505 A US22151505 A US 22151505A US 2006034812 A1 US2006034812 A1 US 2006034812A1
- Authority
- US
- United States
- Prior art keywords
- cells
- tumor
- αgal
- human
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000000981 bystander Effects 0.000 title claims abstract description 16
- 238000001802 infusion Methods 0.000 title abstract description 33
- 238000011282 treatment Methods 0.000 title abstract description 29
- 230000000694 effects Effects 0.000 title abstract description 26
- 241001529936 Murinae Species 0.000 claims abstract description 62
- 230000004044 response Effects 0.000 claims abstract description 29
- 210000003200 peritoneal cavity Anatomy 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 138
- 241000282414 Homo sapiens Species 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 37
- 229960002963 ganciclovir Drugs 0.000 claims description 37
- 230000001177 retroviral effect Effects 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 25
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 108060003306 Galactosyltransferase Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 210000002845 virion Anatomy 0.000 claims 3
- 108700004026 gag Genes Proteins 0.000 claims 2
- 101150098622 gag gene Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 abstract description 16
- 238000002512 chemotherapy Methods 0.000 abstract description 6
- 238000002689 xenotransplantation Methods 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 description 38
- 238000012546 transfer Methods 0.000 description 26
- 210000004881 tumor cell Anatomy 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 19
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 16
- 230000002611 ovarian Effects 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 210000003567 ascitic fluid Anatomy 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 230000002147 killing effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 206010033128 Ovarian cancer Diseases 0.000 description 11
- 230000006023 anti-tumor response Effects 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000000306 recurrent effect Effects 0.000 description 7
- 102100039897 Interleukin-5 Human genes 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 108020004440 Thymidine kinase Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 229940100602 interleukin-5 Drugs 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 108700004025 env Genes Proteins 0.000 description 5
- 101150030339 env gene Proteins 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101150099983 GT gene Proteins 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 4
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 241001364944 Mus terricolor Species 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 241000282520 Papio Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 190000008236 carboplatin Chemical compound 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000009520 phase I clinical trial Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
- 102000030902 Galactosyltransferase Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 2
- 206010025538 Malignant ascites Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010016101 Griffonia simplicifolia lectins Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010061269 Malignant peritoneal neoplasm Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 1
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 101150105073 SCR1 gene Proteins 0.000 description 1
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QIGJYVCQYDKYDW-SDOYDPJRSA-N alpha-D-galactosyl-(1->3)-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000002524 peritoneal carcinoma Diseases 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13071—Demonstrated in vivo effect
Definitions
- Ovarian carcinoma is the most common cause of death from a gynecological malignancy in the United States. Over 2 ⁇ 3 of the patients have advanced stage disease at presentation for which systemic chemotherapy is indicated after surgical debulking. Standard therapy consists of cisplatin or carboplatin with paclitaxel, and excellent response rates are observed; however, recurrence is common, and the majority of patients still die of disease progression. Ovarian cancer has a fairly unique natural history in humans. Even patients with advanced stages of the disease often have their disease confined to their abdomen for extended periods of time. The disease often stays localized to the abdomen and presents great difficulty for the patient by obstruction of the intestines or ureters. This natural history makes the possibility of locally-targeted therapy realistic. As a result, intraperitoneal therapies have been developed for the local administration of chemotherapeutic agents into the peritoneal cavity.
- HSVtk Herpes Simplex Virus thymidine kinase
- Ganciclovir ganciclovir
- HSVtk sensitizes transduced tumor cells to GCV.
- Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy Cancer Res. 46, 5276-5281 (1986); Moolten, F. L. & Wells, J. M., Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors J. Nat. Cancer Inst. 82, 297-300 (1990); Moolten, F. L., Wells, J. M., Heyman, R. A. & Evans, R.
- GCV Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene Human Gene Ther. 1, 125-134 (1990); Plautz, G., Nabel, E. G. & Nabel, G. J., Selective elimination of recombinant genes in vivo with a suicide retroviral vector New Biologist 3(7), 709-715 (1991).
- GCV is phosphorylated by HSVtk resulting in a monophosphate that cellular kinases convert to GCV-triphosphate which inhibits DNA replication and causes cell death.
- VPC vector producer cells
- Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: Strategies for evading the humoral immune response Human Gene Therapy 7, 619-626 (1996); Link, C. J., Levy, J. P., Seregina, T., Atchinson, R. & Moorman, D., in Cancer Gene Therapy (eds Mazarakis, H. & Swart, S. J.) 135-152 (IBC Library Series, London, United Kingdom, 1997).
- the contrast enhancement reported along the needle tracts of VPC injections, as well as the transient volume increase of the tumors immediately after injection was more likely to be the result of antibodies (Ab) and complement-mediated hyperacute rejection against the murine cells.
- M11 murine VPC producing HSVtk retroviral vector were injected into the tumor margin after surgical debulking. Seven days later, patients were treated with GCV. Twelve patients were treated without side effects that the physicians attributed to the VPC or GCV. The authors claimed that the observed responses were secondary to gene therapy. One patient was still alive without evidence of progression by MRI at 2.8 years after the procedure. Eleven of twelve patients had died; nine from tumor progression, one from head trauma, and one from pulmonary embolus. To relate these observations to the gene therapy, the authors suggested several indirect lines of evidence. First, M11 cells could be recovered from surgical drain fluids 24 hours after cell injections. However, M11 VPC were recovered from only 3 out of 6 patients even at this short time point. Furthermore, no viable cells were recovered at later time points.
- Hyperacute rejection of xenografts has been previously explored due to the great interest in using animals as a source of organs or tissues for humans. Strong immunological barriers to xenotransplants can destroy a transplanted solid organ within minutes, a process termed hyperacute rejection.
- This hyperacute rejection model of xenograft survival is typically a vascularized xenograft directly exposed to blood serum. Pruitt, S. K., Kirk, A. D., Bollinger, R. R., Marsh, J., Henry, C., Collins, B. H., Levin, J. L., Mault, J. R., Heinle, J. S., (2004), S., Rudolph, A.
- ⁇ (1,3)GT is expressed in all mammalian species including Mus musculus , but not in Old World primates, apes, or humans.
- Galili U. Shohet, S. B., Kobrin, E., Stults, C. L. & Macher, B. A., Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells J.
- ⁇ (1,3)GT catalyzes the transfer of galactose from uridine diphosphate galactose (UDP-Gal) to the N-acetyl-lactosamine acceptors on carbohydrate side chains in a specific ⁇ (1,3)linkage on glycoproteins or glycolipids (Gal ⁇ 1 ⁇ 4GlcNAc-R).
- Anti- ⁇ gal Ab present in the human serum can recognize this epitope.
- Galili U. Shohet, S. B., Kobrin, E., Stults, C. L. & Macher, B. A., J. Biol. Chem. 263, 17755-62 (1988).
- pre-existing human Ab against ⁇ gal represent almost 1% of total human Ab (Galili, U., Evolution and pathophysiology of the human natural anti-y-galactosyl IgG (anti-Gal) antibody Springer Semin. Immunopathol.
- Neonatal circulating xenoreactive Ab are of the IgG isotype, presumably attained by placental transfer of maternal IgG.
- Murine vector producing cells implanted into humans is another type of xenograft. It has been demonstrated that murine retroviral VPC and the viral vectors they produce express ⁇ gal and, therefore, are lysed by Ab and complement within 30 minutes after being exposed to human serum.
- Viral vectors can efficiently transduce human tumor cells with anti-tumor therapeutic genes.
- porcine ⁇ (1,3)GT As part of a study of blocking retroviral destruction by using human packaging cells, the transfer of the porcine ⁇ (1,3)GT to human fibroblasts was shown to result in sensitivity to Ab and complement destruction.
- Collins, M. K. Takeuchi, Y., Cosset, F. L., Tailor, C. & Weiss, R. A. Development of recombinant retroviruses suitable for in vivo gene delivery Cold Spring Harbor Meeting: Gene Therapy September 1994, 97 (1994).
- the predicted tumor resistance will likely extend to gene therapy as well; for example, our group has demonstrated that resistance to HSVtk gene and GCV killing is common in tumor cells. Seregina, T., Levy, J. & Link, C. in Fourth International Conference on the Gene Therapy of Cancer Vol. 2 (eds Sobol, R. E. & Royston, I.) A332 (Appleton & Lange, San Diego, Calif., 1995). In the future, gene delivery methods that transfer multiple therapeutic genes in concert or genes with multiple mechanisms of action will dominate approaches for cancer treatment.
- VPC could be eliminated using the present invention, thus, taking away the additional risk to the patient of using viral vectors.
- the present invention is able to create anti-tumor responses without the need for gene transfection and addition of a prodrug.
- An object of the invention is a method of tumor treatment.
- Another object of the invention is a method for treating cancer by activation of hyperacute rejection in or near the tumor(s).
- a further object of the invention is a method for inducing an immune reaction to attack tumor cells.
- the present invention induces hyperacute rejection in and/or in the vicinity of a tumor by xenotransplantation/infusion of xenogeneic cells.
- the xenogeneic cells activate the hyperacute rejection response to themselves and induce an immune reaction in which tumor cells are destroyed.
- One mechanism of tumor destruction may be by an innocent bystander effect.
- ganciclovir may be used (see, e.g., U.S. Pat. No. 5,631,236, hereby incorporated by reference).
- FIG. 1 shows gels of PCR analysis of patient 4 who received 680 million murine LTKOSN.1 vector producer cells (VPC) into the peritoneal cavity.
- TOP PCR amplification for the HSVtk gene.
- Positive controls LTKOSN plasmid only (10 fg), A375 human melanoma cells mixed with 0.1%, 0.01%, 0% A375 cells transduced with LTKOSN vector; intraperitoneal tumor biopsy from day ⁇ 1 (before VPC infusion) and 14 days after infusion (before GCV); peritoneal washings obtained at day ⁇ 1 before and days 3 to 35 after VPC infusion.
- HSVtk gene sequence is detected in the day 14 tumor biopsy and on days 3 and 7 after VPC infusion.
- BOTTOM PCR amplification for the viral env gene.
- Positive controls pPAM plasmid containing the viral env gene (10 fg), 0.1% or 0.01% LTKOSN.1 VPC; intraperitoneal tumor biopsy from day ⁇ 1 and 14; peritoneal washings at day ⁇ 1, 3, 7, 14 and 35 after VPC infusion. The env gene sequence is detected in the day 3 and 7 peritoneal washings, but not from the tumor biopsy. Therefore, VPC are lost from the abdominal cavity after day 7.
- FIG. 2 is a graph showing anti- ⁇ gal titer after murine LTKOSN.1 VPC infusion. Data shown for patients 1-9 before (day 0) and on day 14 or 21 after infusion.
- FIG. 3 is a graph showing killing efficiency of patient serum on murine LTKOSN.1 VPC in vitro.
- FIG. 4 is a graph showing killing efficiency of patient peritoneal fluid on murine LTKOSN.1 VPC in vitro.
- FIG. 5 is a graph showing the increase in reactivity of patient's serum against fetal bovine serum (FSB) following murine VPC LTKOSN.1 infusion (fold).
- FIG. 6 is a graph of levels of IL-5 in peritoneal fluid after murine LTKOSN.1 VPC infusion.
- ELISA assay was performed to measure the levels of IL-5 from peritoneal washing samples both before and after murine VPC infusions. Peak levels of IL-5 were found 7 to 14 days after VPC infusion. This IL-5 response overlaps closely the period during which immune destruction and elimination of the cells occurs.
- Murine cells express a surface glycosylation pattern that is not present on human cells.
- the murine ⁇ (1,3)galactosyltransferase [ ⁇ (1,3)GT] enzyme adds ⁇ (1,3)galactosyl epitopes ( ⁇ gal) onto glycoproteins and glycolipids.
- Pre-existing human antibody can bind these epitopes and fix complement resulting in the direct lysis of the murine cells.
- Our data suggests that an innocent bystander effect then occurs which induces the destruction of adjacent cancer cells and possibly stimulates anti-tumor immunity. Though it is believed the bystander effect is responsible for destruction of the tumor cells, a different or several mechanisms may be responsible.
- the present invention seeks to shift the current understanding of published trials stating that HSVtk and ganciclovir (GCV) gene therapy is efficacious for the treatment of solid tumors in adults. These trials were designed with the idea that murine VPC xenografts would provide the production of retroviral vectors within solid tumors and efficiently transfer the HSVtk gene. This gene transfer was then expected to sensitize solid tumors to GCV. Furthermore, a bystander effect caused by metabolic cooperation was to enhance the effect, so that if only a small portion of the tumor was transduced with HSVtk, then the entire tumor could be destroyed. In cell culture and animal models of HSVtk and GCV therapy, 10-20% of the tumor needed to express the HSVtk gene to obtain complete response.
- GCV ganciclovir
- VPC implantation of VPC is superior to implanting HSVtk pre-transduced cells alone to increase the delivery of the HSVtk gene.
- this approach is often not successful even when 50% of the cells are pretransduced with HSVtk for a variety of human tumor xenografts (Link, unpublished observations).
- LTKOSN.1 VPC murine retroviral LTKOSN.1 VPC for in vivo transfer of the HSVtk gene. All patients had failed prior therapy with paclitaxel and either cisplatin or carboplatin.
- LTKOSN.1 VPC were infused into the peritoneal cavity in doses from 1 ⁇ 10 6 to 1 ⁇ 10 8 cell/kg. After 4 weeks, patients were treated with GCV for 2 weeks. Viable VPC were recovered from peritoneal washes on day +3 and/or day +7 after infusion at the two highest dose levels. The recovered VPC were still able to produce high titer LTKOSN retroviral vector.
- VPC were detectable by PCR up to day +7, but at day +14 none were detected.
- Tumor tissue obtained on day +14 prior to first GCV injection were positive for the HSVtk gene by PCR.
- Four of ten evaluable patients demonstrated some evidence of anti-tumor response.
- One patient had a complete resolution of a 2 cm mass on CT scan and a 70% reduction of CA125. Of the remaining 3, first patient had a partial, second patient a minor, and the third patient showed a mixed response to the treatment.
- the patient with the mixed response demonstrated significant resolution of malignant ascites prior to GCV infusion, but developed a malignant pleural effusion.
- Quantitative PCR analysis demonstrated less than 1% gene transfer into intraperitoneal tumor biopsies prior to GCV administration. All patients were treated as outpatients.
- any xenogeneic cells which will activate the hyperacute rejection will be effective in the invention.
- One of ordinary skill in the art would be able to determine which cells other than murine cells which will be safe and effective. There are many commercial and academic sources of cell lines. Additionally, one of ordinary skill would be able to develop cells lines to use in the present invention.
- the Examples show that the xenogeneic cells were infused into the peritoneal cavity in the vicinity of the tumor using a catheter.
- One of ordinary skill would be able to determine other methods of presenting the xenogeneic cells to the body in order to induce the hyperacute rejection and bystander effect.
- the dose levels of xenogeneic cells that have been used are shown in the Examples. One of ordinary skill would be able to determine a dose level appropriate for the tumor and the patient which is both safe and effective.
- LTKOSN is a retroviral vector derived from the Moloney murine leukemia virus (MoMLV).
- the vector LTKOSN contains a Herpes Simplex type I thymidine kinase (HSVtk) gene cDNA that is transcribed from the viral long terminal repeat (LTR) and a bacterial neomycin resistance (neo r ) gene transcribed from an internal SV40 (simian virus 40) early promoter (LTR-HSVtk-SV-neo r -LTR) in the LXSN backbone.
- HSVtk Herpes Simplex type I thymidine kinase
- neo r bacterial neomycin resistance gene transcribed from an internal SV40 (simian virus 40) early promoter
- This vector has been modified for increased safety by alteration of the gag start codon to a stop codon, and by elimination of viral sequences to minimize the potential for the development of replication-compete
- the present invention was used to treat ovarian and fallopian cancer which are solid tumors.
- One of ordinary skill would be able to determine other tumors which will respond to the treatment of the present invention.
- VPC murine vector producer cells
- SCR1 is a soluble form of complement receptor 1 that binds activated complement and prevents the attack complex from damaging the cell membrane.
- LTKOSN.1 VPC murine retroviral LTKOSN.1 VPC for in vivo transfer of the HSVtk gene. All patients had failed prior therapy with paclitaxel and either cisplatin or carboplatin. All patients were treated as outpatients.
- LTKOSN.1 VPC were infused intraperitoneally with doses from 1 ⁇ 10 6 to 1 ⁇ 10 8 cell/kg. After 2 weeks, patients were treated for two weeks with ganciclovir (GCV). The data is detailed in Tables 1 and 2. TABLE 1 Clinical Outcome in Ovarian Cancer Patients Treated with LTKOSN.1 VPC.
- LTKOSN.1 murine VPC were recovered from peritoneal wash samples of patients on day +3 and/or day +7 after infusion at the two highest dose levels.
- the recovered VPC cultures were G418 resistant, and their supernatants contained high titers of LTKOSN retroviral vector similar to those produced by LTKOSN.1 VPC used for infusion into patients (1-1.5 ⁇ 10 5 cfu/ml).
- VPC were detectable by PCR up to day +7, but at day +14 none were detected ( FIG. 1 )
- Replication competent retrovirus (RCR)S + L ⁇ assays were conducted on peripheral blood lymphocytes (PBL) of patients. Cells were co-cultured with Mus dunni cells for two weeks (four passages). After two weeks, supernatants were collected and centrifuged. The supernatant was then placed on PG-4 cells (40 to 60% confluent) for two hours. The supernatant was removed and D10 (DMEM, 10% fetal bovine serum, L-glutamine) added. After four to seven days, PG-4 cells were observed for development of foci. MMLV 4070A was used as the positive control, and Mus dunni cells alone were used as the negative control. No RCR was present in PBL samples obtained up to one year after VPC infusion as detected in co-cultivation with Mus dunni followed by S+L-assay.
- PBL peripheral blood lymphocytes
- Genomic DNA was isolated from 3 ml of whole blood using the Genomic DNA Purification Kit (Promega or Sigma). Tumors were digested by mincing the tissue and adding tumor lysis solution (2 mg/ml Collagenase, Type II; 0.2 mg/ml DNAaseI; 2.1 ⁇ g/ml Ilyaluronidase, Type V). The tumor was dissociated on a slow rocker at RT for 1 hour, and cells were collected by filtering through a nylon mesh. The peritoneal wash samples were centrifuged to collect all the cells, and DNA was isolated using the Genomic DNA Isolation Kit (Sigma). Isolation of genomic DNA from A375 LTKOSN.1 cells diluted with A375 NV cells was used to create 10 ⁇ 2 , 10 ⁇ 3 , 10 ⁇ 4 , and 10 ⁇ 5 cell dilutions for PCR controls.
- tumor lysis solution 2 mg/ml Collagenase, Type II; 0.2 mg/ml DNAaseI; 2.1
- MLVENV-F (5′-ACCTGGAGAGTCACCAACC-3′) SEQ ID NO:1 and MLVENV-R (5′-TACTITGGAGAGGTCGTAGC-3′) SEQ ID NO:2 were designed to amplify a 411 bp fragment of the env gene.
- the PCR reaction was 3 min. at 94° C., followed by 30 cycles of 94° C. for 20 seconds, 68° C. for 1 minute, and 72° C. for 1 minute, with a final extension of 10 minutes at 72° C.
- the reaction mix was 500 ng of genomic DNA (sample), 25 pmoles of each primer, 1 ⁇ PCR buffer, 0.2 mM dNTPs, 1.25 MM MgCl 2 , and 1.25 U Taq.
- A375 NV cells and a sample containing no genomic DNA were used as negative controls.
- 100 fg of pPAM3 was used as a positive control for each sample.
- 500 ng of each A375 LTKOSN.1 dilution of genomic DNA (1 ⁇ 10 ⁇ 4 and 5 ⁇ 10 ⁇ 4 ) was used as additional controls.
- PCR product from blood lymphocytes and controls were transferred to membrane using a slot blot.
- the env probe was labeled with ( 32 P)dCTP by the random priming technique (Boehringer Mannheim). The blots were hybridized overnight at 42° C. in Hybridisol (Oncor) and washed. No env gene sequence was detected by PCR in PBL samples obtained up to one year after VPC infusion.
- PCR primers JMTKO1 5′ TAT AGA CGG TCC TCA CGG GAT 3′ SEQ ID NO:3 and JMTKO3 5′ TCA TGC TGC CCA TAA GGT AT 3′
- SEQ ID NO:4 were designed to amplify a 388 bp fragment of the TK gene.
- the reaction mix contained 500 ng of genomic DNA sample.
- A375 NV cells and a sample containing no genomic DNA was used as negative controls.
- 100 fg of pLTKOSN.1 was used as a positive control for each sample.
- PCR product from blood lymphocytes and controls were transferred to membrane using a slot blot.
- a TK probe was labeled with ( 32 P)dCTP by the random priming technique (Boehringer Mannheim).
- PCR products from peritoneal wash and tumor samples were run out on 1.5% TBE gels and Southern transferred onto nylon membrane following manufacturer's instructions. No HSVtk gene transfer into PBL from patient blood samples up to 3 months after VPC infusion were detected by PCR in any patient.
- patient #8 who manifested the best and most durable anti-tumor response observed had a high induced serum titer of anti- ⁇ gal Ab (32-fold increase) and a rapid up-slope in the ability of her peritoneal fluid to kill murine VPC in the ex vivo assay.
- These data support a correlation between anti- ⁇ gal immunity and tumor response, but in this Phase I trial GCV was administered 14 days after VPC, and this temporal overlap makes conclusions about causation difficult.
- the proposed trial design of waiting 4 weeks after VPC infusion to treat with GCV may allow these effects to be separated. Changes in the peritoneal cavity may alter the ability of the immune system to detect these tumors.
- Peritoneal wash samples were centrifuged at 250 ⁇ g, and the cell pellets were resuspended in DMEM supplemented with 10% FBS (Gibco) and aliquoted. One mg/ml of G418 (Gibco) was added to one aliquot, and cells were incubated at 37° C., 5% CO 2 . Cells in samples containing VPC reached confluency in approximately 10 days after cell culture initiation. Cells were cultured in medium containing one mg/ml G418 for two additional weeks, then the supernatant was used to infect IGROV human ovarian carcinoma cells in standard vector titration assay as established at our Institute. The data on the recovered VPC is shown in Table 2 and clearly demonstrates that high titer VPC can be recovered up to 7 days after intraperitoneal infusions.
- ELISA for anti-FBS was performed in Nuclon 96-well plates were coated with BSA by filling wells with 100 ⁇ l of 5% BSA in PBS and incubating at 4° C. overnight. The plate was washed four times with PBS, and 150 ⁇ l of blocking buffer (1% dry milk; 0.1% SDS) was added and incubated at room temperature for one hour. Primary antibody (100 ⁇ l diluted patient serum (1:50) samples followed by serial dilution) was added following 4 washes and incubated for one hour. After four washes, 150 ⁇ l of blocking buffer was added, and the plate was incubated two hours.
- blocking buffer 1% dry milk; 0.1% SDS
- the secondary horseradish peroxidase-conjugated antibody [100 ⁇ l of antibody; 1/40,000 dilution of goat anti-human (Pierce) for patient samples; 1/15,000 dilution of goat anti-bovine (Kirkegaard & Perry) for positive control] was added and incubated for one hour. Following four washes, 100 ⁇ l of room temperature TMB (Sigma) substrate was added and color was allowed to develop for 15 minutes. The reaction was stopped by adding 100 ⁇ l of 1 M H 2 SO 4 . Absorbance values were read at 450 nm on an ELISA plate reader. Only 3 patients developed anti-FBS Ab (out of 9 tested).
- This eukaryotic expression vector was transfected into human A375 melanoma tumor cells that were then exposed to human serum. Many A375 subclones were obtained, and data for three representative examples are presented. Clones A375 ⁇ G.7 and A375 ⁇ G.8 showed significant sensitivity to serum killing while clone A375 ⁇ G.11 did not (Table 3). TABLE 3 Effect of human serum on A385 ⁇ G cells.
- the next step in acquiring evidence needed to pursue this strategy was to demonstrate in vivo differences in an animal model.
- the ⁇ (1,3)GT gene can also sensitize cells to normal human serum when transferred by a Herpes simplex vector into ovarian or colon carcinoma cells.
- Eosinphilia Occurs Within the Peritoneal Cavity After Xenotransplants in Humans
- the Phase II trial will involve 43 adult women with recurrent or refractory ovarian, fallopian, or peritoneal carcinoma, will be evaluated for the extent and location(s) of their disease before being entered into the study. Patients will have a CT scan and laparotomy or laparoscopy with biopsy to confirm the diagnosis. During laparoscopy, eligible patients will have a peritoneal dialysis catheter placed. HSVtk VPC will be infused into the peritoneal space over 15-60 minutes in a total volume of one to two liters of plasmalyte. Four weeks later, GCV will be administered over one hour at 5 mg/kg/dose IV b.i.d. for 14 days. Patients may receive up to three cycles of therapy if no tumor regression is observed. After the completion of therapy, patients who continue to show evidence of response will be followed every three months for the first year.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for treating tumors. Through infusion or xenotransplantation of xenogeneic cells, such as infusion of murine cells into the peritoneal cavity of humans, a hyperacute rejection response to the cells is induced. This in turn creates a bystander effect to the tumor. This effect creates tumor regression. This treatment can be used alone or in conjunction with gene therapy or chemotherapy treatments.
Description
- This application claims priority under 35 U.S.C. § 119 of U.S. Provisional Patent Application No. 60/138,038 filed Jun. 8, 1999, and from U.S. application Ser. No. 09/589,255 filed Jun. 1, 2000, which applications are hereby incorporated by reference in their entirety.
- Ovarian carcinoma is the most common cause of death from a gynecological malignancy in the United States. Over ⅔ of the patients have advanced stage disease at presentation for which systemic chemotherapy is indicated after surgical debulking. Standard therapy consists of cisplatin or carboplatin with paclitaxel, and excellent response rates are observed; however, recurrence is common, and the majority of patients still die of disease progression. Ovarian cancer has a fairly unique natural history in humans. Even patients with advanced stages of the disease often have their disease confined to their abdomen for extended periods of time. The disease often stays localized to the abdomen and presents great difficulty for the patient by obstruction of the intestines or ureters. This natural history makes the possibility of locally-targeted therapy realistic. As a result, intraperitoneal therapies have been developed for the local administration of chemotherapeutic agents into the peritoneal cavity.
- Gene therapy is among the experimental strategies for patients with cancer who have failed standard therapy. Despite more than 100 gene therapy trials, evidence of success is very limited. Roth, J. A., Cristiano, R. J., Roth, J. A. & Cristiano, R. J., Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89(1), 21-39 (1997). One strategy which has been explored for treating cancer is the artificial creation of differences between normal and neoplastic cells through prophylactic use of gene insertion techniques. In other words, manufacturing biochemical differences which can be exploited to systematically and specifically target neoplastic cells for destruction. Gene insertion protocols are used to artificially manufacture biochemical differences in target tumor cells which are then exploited to selectively kill these cells. One system which has received much attention to date is the Herpes Simplex Virus Ganciclovir System.
- Transformation of tumor cells with the gene encoding Herpes Simplex Virus thymidine kinase (HSVtk) and subsequent treatment with anti-viral agents such as ganciclovir (GCV) has been previously accomplished and has proven to be operable in vivo in animals and humans. See Gene Therapy for the Treatment of Recurrent Pediatric Malignant Astrocytomas With In Vivo Tumor Transduction With Herpes Simplex Thymidine Kinase Gene/Ganciclovir System, Raffel, C. et al., Human Gene Therapy 5(7), p. 863-90, July 1994. The HSVtk gene is a negative selectable marker or “suicide” gene of which most investigators in the field are well aware and versed in how the system is supposed to function. HSVtk sensitizes transduced tumor cells to GCV. Moolten, F. L., Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy Cancer Res. 46, 5276-5281 (1986); Moolten, F. L. & Wells, J. M., Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors J. Nat. Cancer Inst. 82, 297-300 (1990); Moolten, F. L., Wells, J. M., Heyman, R. A. & Evans, R. M., Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene Human Gene Ther. 1, 125-134 (1990); Plautz, G., Nabel, E. G. & Nabel, G. J., Selective elimination of recombinant genes in vivo with a suicide retroviral vector New Biologist 3(7), 709-715 (1991). GCV is phosphorylated by HSVtk resulting in a monophosphate that cellular kinases convert to GCV-triphosphate which inhibits DNA replication and causes cell death. An interesting in vitro and in vivo observation with HSVtk is that only a portion of tumor cells need to be transduced with this gene to induce complete tumor destruction. This metabolic cooperation is a form of “bystander effect” and is due in large part to the transfer of phosphorylated GCV between cells through gap junctions. Moolten, F. L., Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy Cancer Res. 46, 5276-5281 (1986); Culver, K. W., Ram, Z., Walbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors Science 256, 1550-1552 (1992); Nielsen, C. S., Moorman, D. W., Levy, J. P. & Link, C. J., Jr., Herpes simplex thymidine kinase gene transfer is required for complete regression of murine colon adenocarcinoma Am. Surg. 63(7), 617-620 (1997); Bi, W. L., Parysek, L. M., Warnick, R. & Stambrook, P. J., In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy Hum. Gene Ther. 4, 725-731 (1993); Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified Cancer Res. 53, 5274-5283 (1993); Ishii-Morita, H., Agbaria, R., Mullen, C. A., Hirano, H., Koeplin, D. A., Ram, Z., Oldfield, E. H., Johns, D. G., and Blaese, R. M. Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment Gene Ther. 4(3), 244-51 (1997); Link, C. J., Jr., Kolb, E. M. & Muldoon, R. R., Preliminary in vitro efficacy and toxicities studies of the herpes simplex thymidine kinase gene system for the treatment of breast cancer Hybridoma 14(2), 143-7 (1995); Samejima, Y. & Meruelo, D., ‘Bystander killing’ induces apoptosis and is inhibited by forskolin Gene Therapy 2, 50-58 (1995); Vrionis, F. D., Wu, J. K, Qi, P., Waltzman, M., Cherington, V., and Spray, D. C. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions Gene Ther. 4(6), 577-85 (1997). The implantation of vector producer cells (VPC) to deliver genes, such as the HSVtk gene, into tumor cells was first demonstrated in a brain tumor model by engrafting lacZ VPC into rodents with C6 glioma tumors. Short, M. P., Choi, B. C., Lee, J. K., Malick, A., Breakefield, X. O., and Martuza, R. L. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line J. Neurosci. Res. 27, 427-439 (1990). In these reported animal tumor models, all of the rodents are αgal+. Since these were αgal+ models, hyperacute rejection is not contributing to the observed responses with the HSVtk system. A human, however, is different.
- Three prior human trials of murine HSVtk VPC have been reported; two for treatment of brain tumors and one for melanoma. Results from the first clinical trial conducted at the NCI using murine VPC xenografts were recently reported in Nature Medicine. Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., Katz, D., Blaese, R. M., and Oldfield, E. H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nature Med. 3, 1354-1361 (1997). This trial used multiple stereotaxic injections to introduce murine HSVtk VPC into the enhancing portion of brain tumors. Anti-tumor activity was observed in selected local tumor deposits in 5 of 19 tumors injected in 13 patients. Ram, Z. et al., Nature Med. 3, 1354-1361 (1997). It is important to note that very limited (minimal) gene transfer was observed. The stereotaxic injections required multiple needle passages to try to distribute the VPC throughout the tumors resulting in severe hemorrhage that required surgery in 2 patients and MRI-visible bleeding in most of the other tumors. The authors theorized that the observed responses were secondary to the cell-to-cell transfer of phosphorylated GCV as “the major mechanism” of the bystander effect and concluded that “non-immune bystander mechanisms were critical.” Ram, Z. et al., Nature Med. 3, 1354-1361 (1997). They further stated that the observed responses were “probably not a result of immune mechanisms.” In light of data presented in this application and data from others demonstrating rapid destruction of murine VPC by human serum, these conclusions are unwarranted. Rollins, S. A., Birks, C. W., Setter, E., Squinto, S. P. & Rother, R. P., Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: Strategies for evading the humoral immune response Human Gene Therapy 7, 619-626 (1996); Link, C. J., Levy, J. P., Seregina, T., Atchinson, R. & Moorman, D., in Cancer Gene Therapy (eds Mazarakis, H. & Swart, S. J.) 135-152 (IBC Library Series, London, United Kingdom, 1997). We suggest that the contrast enhancement reported along the needle tracts of VPC injections, as well as the transient volume increase of the tumors immediately after injection, was more likely to be the result of antibodies (Ab) and complement-mediated hyperacute rejection against the murine cells. Of note, the authors did report an increase in VPC binding Ab that peaked 21-142 days after VPC injection; these Ab may represent anti-αgal Ab. Ram, Z. et al., Nature Med. 3, 1354-1361 (1997). Other groups have shown that anti-pig Ab present in human serum are predominantly anti-αgal IgM Ab. Vaughan, H. A., McKenzie, I. F. & Sandrin, M. S. Biochemical studies of pig xenoantigens detected by naturally occurring human antibodies and the galactose alpha(1,3)galactose reactive lectin Transplantation 59(1), 102-9 (1995). The time frame of Ab titer increase is similar to that reported for diabetic patients transplanted with porcine islet xenografts and with our results with murine VPC intraperitoneal infusions discussed below. Galili, U., Tibell, A., Samuelsson, B., Rydberg, L. & Groth, C. G. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters Transplantation 59 (11), 1549-56 (1995).
- A second brain tumor trial was recently reported by Klaztmann and colleagues. Klatzman, D., Valery, C. A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzman, J.-L., Philippon, J., and Glioblastoma, S.G.o.G.T.f. A phase I/II dose escalation study of Herpes
simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma Human Gene Ther. 9, 2595-2604 (1998). M11 murine VPC producing HSVtk retroviral vector were injected into the tumor margin after surgical debulking. Seven days later, patients were treated with GCV. Twelve patients were treated without side effects that the physicians attributed to the VPC or GCV. The authors claimed that the observed responses were secondary to gene therapy. One patient was still alive without evidence of progression by MRI at 2.8 years after the procedure. Eleven of twelve patients had died; nine from tumor progression, one from head trauma, and one from pulmonary embolus. To relate these observations to the gene therapy, the authors suggested several indirect lines of evidence. First, M11 cells could be recovered from surgical drain fluids 24 hours after cell injections. However, M11 VPC were recovered from only 3 out of 6 patients even at this short time point. Furthermore, no viable cells were recovered at later time points. Again, neurosurgical procedures with local tumor resections are operations with active bleeding and oozing into the tumor bed where the cells were injected. In fact, a blood-brain barrier that has been quoted by a number of groups to protect murine VPC (Ram, Z., J. Neurosurg. 79, 400-7 (1993)) is mechanically destroyed by the scalpel during major surgical debulking. Thus, M11 cells were most likely quickly lysed by the presence of human serum. The ability to recover a few viable M11 cells from thesurgical drain 1 day after up to 9.8×106 cells/cm2 were injected is not compelling evidence that gene transfer is accounting for these observations. The second indirect evidence proposed was that GCV plasma levels were in a therapeutic range to kill HSVtk expressing cells. It is not understood how the presence of an adequate GCV level provides evidence of causation without HSVtk gene transfer data. No gene transfer into glioblastoma cells was reported. The imaging and pathologic data from this trial does suggest that patients who did not demonstrate MRI progression at 4 months after VPC injection do show some efficacy; however, the relationship between these observed responses and HSVtk and GCV is highly speculative. - One other study was performed on melanoma patients with non-CNS malignancy. Klatzman, D. et al., Human Gene Ther. 9, 2585-2594 (1998). Eight patients were treated by the direct injection of murine M11 packaging cells that produced HSVtk vector. The total cell dose ranged from 8×107 to 12.5×108 cells that were directly injected into tumors. Inflammatory reactions were common immediately after these xenogeneic VPC were injected. A rapid increase in tumor size was noted that peaked 24 hours later. The investigators attributed these effects to known pre-existing antibodies against xenogeneic antigens present on murine cells. This suggestion supports our findings. The very limited anti-tumor effects were some areas of local necrosis noted on biopsy samples. The lack of significant efficacy was attributed to poor gene transfer (<1% or none detected by PCR). Side effects of therapy consisted chiefly of local inflammatory reactions or fever when multiple injections were administered. This group suggested that murine VPC survival was enhanced by using intravenous immunoglobulin to delay xenogeneic hyperacute rejection. Gautreau, C., Kojima, T., Woimant, G., Cardoso, J., Devilier, P., and Houssin, D. Use of intravenous immunoglobulin to delay xenogeneic
hyperacute rejection Transplantation 9, 903-907 (1995). - Hyperacute rejection of xenografts has been previously explored due to the great interest in using animals as a source of organs or tissues for humans. Strong immunological barriers to xenotransplants can destroy a transplanted solid organ within minutes, a process termed hyperacute rejection. This hyperacute rejection model of xenograft survival is typically a vascularized xenograft directly exposed to blood serum. Pruitt, S. K., Kirk, A. D., Bollinger, R. R., Marsh, J., Henry, C., Collins, B. H., Levin, J. L., Mault, J. R., Heinle, J. S., Ibrahim, S., Rudolph, A. R., Baldwin, I., William, M., and Sanfilippo, F. The effect of soluble
complement receptor type 1 on hyperacute rejection of porcine xenografts Transplantation 57, 363-370 (1994). Research has demonstrated that hyperacute rejection with porcine xenografts transplanted into baboons occurs secondary to porcine α(1,3)galactosyltransferase [α(1,3)GT] gene expression and α(1,3)galactosyl epitopes (αgal) presentation. Pruitt, S. K. et al., Transplantation 57, 363-370 (1994); Platt, J. L., Vercellotti, G. M., Dalmasso, A. P., Matas, A. J., Bolman, R. M., Najarian, J. S., and Bach, F. H. transplantation of discordant xenografts: a review of progress Immunol. Today 17, 450-457 (1990). The enzyme α(1,3)GT is expressed in all mammalian species including Mus musculus, but not in Old World primates, apes, or humans. Galili, U. Shohet, S. B., Kobrin, E., Stults, C. L. & Macher, B. A., Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells J. Biol. Chem. 263(33), 17755-62 (1988). The α(1,3)GT gene is not active in humans due to the presence of two base pair frameshift mutations. Larsen, R. D., Rivera-Marrero, C. A., Ernst, L. K., Cummings, R. D. & Lowe, J. B., Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase cDNA J. Biol. Chem. 265(12), 7055-61 (1990). α(1,3)GT catalyzes the transfer of galactose from uridine diphosphate galactose (UDP-Gal) to the N-acetyl-lactosamine acceptors on carbohydrate side chains in a specific α(1,3)linkage on glycoproteins or glycolipids (Galβ1→4GlcNAc-R). - Galβ1→4GlcNAc-R+UDP-Gal→Galα1→3Galβ1→4GlcNAc-R Anti-αgal Ab present in the human serum can recognize this epitope. Galili, U. Shohet, S. B., Kobrin, E., Stults, C. L. & Macher, B. A., J. Biol. Chem. 263, 17755-62 (1988). In fact, pre-existing human Ab against αgal represent almost 1% of total human Ab (Galili, U., Evolution and pathophysiology of the human natural anti-y-galactosyl IgG (anti-Gal) antibody Springer Semin. Immunopathol. 15, 155-171 (1993)) and are the basis for complement-mediated hyperacute rejection. Sandrin, M. S., Vaughan, H. A., Dabkowski, P. L. & McKenzie, I. F. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes Proc. Natl. Acad. Sci. U.S.A. 90(23), 11391-5 (1993). Human anti-αgal Ab are thought to arise in response to αgal structures on the surface of normal GI flora. The translocation of viable bacteria from the enteric lumen to the mesenteric lymph nodes is thought to stimulate the host immune response. Neonatal humans and baboons compared to their respective adults have very low titers of anti-αgal IgM Ab, the isotype most effective in binding complement. Xu, H., Edwards, N. M., Dong, X. & Michler, R. E. Age-related development of human preformed anti-porcine endothelial cell xenoantibody J. Thorac. Cardiovasc. Surg. 15, 1023 (1995); Minanov, O. P., Itescu, S., Neethling, F. A., Morgenthau, A. S., Kwiatkowski, P., and Cooper, D. K. Anti-gal IgG antibodies in sera of newborn humans and baboons and its significance pig xenotransplantation Transplantation 63, 182 (1997). Neonatal circulating xenoreactive Ab are of the IgG isotype, presumably attained by placental transfer of maternal IgG. Xu, H., Edwards, N. M., Dong, X. & Michler, R. E., J. Thorac. Cardiovasc. Surg. 15, 1023 (1995); Minanov, O. P. et al., Transplantation 63, 182 (1997); Galili, U., Springer Semin. Immunopathol. 15, 155 (1993). Since newborn gut is sterile, there is a time period in which newborn primates are not exposed to bacterial αgal moieties and, thus, lack de novo Ab directed against these epitopes.
- Murine vector producing cells implanted into humans is another type of xenograft. It has been demonstrated that murine retroviral VPC and the viral vectors they produce express αgal and, therefore, are lysed by Ab and complement within 30 minutes after being exposed to human serum. Link, C. J., Levy, J. P., Seregina, T., Atchinson, R. & Moorman, D., Cancer Gene Therapy (eds Mazarakis, H. & Swart, S. J.) 135-152 (IBC Library Series, London, United Kingdom, 1997); Welsh, R. M., Cooper, N. R., Jensen, F. C. & Oldstone, M. B., Human serum lyses RNA tumor viruses Nature 257, 612-614 (1975); Rother, R. P., Fodor, W. L., Springhorn, J. P., Birks, C. W., Setter, E., Sandrin, M. S., Squinto, S. P., and Rollins, S. A. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody J. Exp. Med. 182(5), 1345-55 (1995). The effect of this serum inactivation on VPC and retroviruses is due to αgal expression on the cells. Link, C. J., Levy, J. P., Seregina, T., Atchinson, R. & Moorman, D., Cancer Gene Therapy (eds Mazarakis, H. & Swart, S. J.) 135-152 (IBC Library Series, London, United Kingdom, 1997); Rother, R. P. et al., J. Exp. Med. 182, 1345-55 (1995); Rother, R. P., Squinto, S. P., Mason, J. M. & Rollins, S. A., Protection of retroviral vector particles in human blood through complement inhibition Hum. Gene Ther. 6(4), 429-35 (1995).
- Viral vectors can efficiently transduce human tumor cells with anti-tumor therapeutic genes. As part of a study of blocking retroviral destruction by using human packaging cells, the transfer of the porcine α(1,3)GT to human fibroblasts was shown to result in sensitivity to Ab and complement destruction. Collins, M. K., Takeuchi, Y., Cosset, F. L., Tailor, C. & Weiss, R. A. Development of recombinant retroviruses suitable for in vivo gene delivery Cold Spring Harbor Meeting: Gene Therapy September 1994, 97 (1994). We have found that the retroviral transduction of human tumor cells with the α(1,3)GT gene resulted in its expression. These human cells displayed αgal and became sensitive to human serum. In this project, murine VPC are employed to deliver retroviral vector to intraperitoneal ovarian tumors. We are interested in the biology of glycosylation and the immunologic effect of αgal epitopes. Therefore, the project goal is to further understand mechanisms of hyperacute rejection. Hyperacute rejection may cause a strong intraperitoneal inflammatory response, that through an innocent bystander mechanism, destroys ovarian cancer cells. The process of local tumor destruction might result in the disruption of tumor anergy. This has been a common strategy in gene modification trials. Previous attempts of immunotherapy have mainly employed single cytokine molecules (e.g., IL-2, GM-CSF) (Golumbek, P. T., Lazenby, A. J., Levitskky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 Science 254, 713-716 (1991); Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity Proc. Natl. Acad. Sci. (USA) 90, 3539-3543 (1993); Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an
antitumor response Cell 60, 397-403 (1990)) or single rejection antigens (e.g., HLA B7, melanoma specific tumor antigen). Nabel, G. J., Nabel, E., Yang, Z., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A. E. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans Proc. Natl. Acad. Sci. (USA) 90, 11307-11311 (1993); Reeves, M. E., Royal, R. E., Lam, J. S., Rosenberg, S. A. & Hwu, P. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene Cancer Res. 56(24), 5672-7 (1996). - Since anti-tumor gene therapy requires highly efficient gene transfer and expression of therapeutic genes (Roth, J. A., Cristiano, R. J., Roth, J. A. & Cristiano, R. J. Gene therapy for cancer: what we have done and where are we going? J. Natl. Cancer Inst. 89(1), 21-39 (1997)) and the Goldie-Coldman hypothesis predicts that spontaneous mutations in cancer cells provide resistance to chemotherapy and that therapeutic failures are directly related to tumor burden (Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat. Rep. 63(11-12), 1727-33 (1979)), multiple, independent therapeutic targets need to be attacked for success. The predicted tumor resistance will likely extend to gene therapy as well; for example, our group has demonstrated that resistance to HSVtk gene and GCV killing is common in tumor cells. Seregina, T., Levy, J. & Link, C. in Fourth International Conference on the Gene Therapy of Cancer Vol. 2 (eds Sobol, R. E. & Royston, I.) A332 (Appleton & Lange, San Diego, Calif., 1995). In the future, gene delivery methods that transfer multiple therapeutic genes in concert or genes with multiple mechanisms of action will dominate approaches for cancer treatment.
- All references cited throughout this application are hereby incorporated by reference.
- Based on the foregoing, it is desirable that a less complicated system without use of vectors be available. Using VPC could be eliminated using the present invention, thus, taking away the additional risk to the patient of using viral vectors. The present invention is able to create anti-tumor responses without the need for gene transfection and addition of a prodrug.
- An object of the invention is a method of tumor treatment.
- Another object of the invention is a method for treating cancer by activation of hyperacute rejection in or near the tumor(s).
- A further object of the invention is a method for inducing an immune reaction to attack tumor cells.
- These and other objects, features, and advantages will become apparent after review of the following description and claims of the invention which follow.
- The present invention induces hyperacute rejection in and/or in the vicinity of a tumor by xenotransplantation/infusion of xenogeneic cells. The xenogeneic cells activate the hyperacute rejection response to themselves and induce an immune reaction in which tumor cells are destroyed. One mechanism of tumor destruction may be by an innocent bystander effect.
- It may be possible to add to this effect by infusing cells which transfect the tumor cells with a gene that the immune system will respond to, for example, one which creates α(1,3)galactosyl epitopes in a human system (see, e.g., U.S. Pat. No. 5,869,035, hereby incorporated by reference).
- Additionally, subsequent treatment with a prodrug which is activated by the gene which was introduced may be added to the therapy. For example, if the HSVtk gene is introduced, ganciclovir may be used (see, e.g., U.S. Pat. No. 5,631,236, hereby incorporated by reference).
-
FIG. 1 shows gels of PCR analysis ofpatient 4 who received 680 million murine LTKOSN.1 vector producer cells (VPC) into the peritoneal cavity. TOP: PCR amplification for the HSVtk gene. Positive controls: LTKOSN plasmid only (10 fg), A375 human melanoma cells mixed with 0.1%, 0.01%, 0% A375 cells transduced with LTKOSN vector; intraperitoneal tumor biopsy from day −1 (before VPC infusion) and 14 days after infusion (before GCV); peritoneal washings obtained at day −1 before anddays 3 to 35 after VPC infusion. HSVtk gene sequence is detected in theday 14 tumor biopsy and ondays day day 7. -
FIG. 2 is a graph showing anti-αgal titer after murine LTKOSN.1 VPC infusion. Data shown for patients 1-9 before (day 0) and onday -
FIG. 3 is a graph showing killing efficiency of patient serum on murine LTKOSN.1 VPC in vitro. -
FIG. 4 is a graph showing killing efficiency of patient peritoneal fluid on murine LTKOSN.1 VPC in vitro. -
FIG. 5 is a graph showing the increase in reactivity of patient's serum against fetal bovine serum (FSB) following murine VPC LTKOSN.1 infusion (fold). -
FIG. 6 is a graph of levels of IL-5 in peritoneal fluid after murine LTKOSN.1 VPC infusion. ELISA assay was performed to measure the levels of IL-5 from peritoneal washing samples both before and after murine VPC infusions. Peak levels of IL-5 were found 7 to 14 days after VPC infusion. This IL-5 response overlaps closely the period during which immune destruction and elimination of the cells occurs. - It has been found that there is an anti-tumor response in women with recurrent ovarian cancer treated with LTKOSN.1 murine VPC and GCV due to the induced immune effect mediated by the activation of hyperacute rejection against non-primate cells that are infused to produce murine retroviral vectors in situ which is prior to any effect by the transfection of the cells or activation of the GCV.
- Murine cells express a surface glycosylation pattern that is not present on human cells. The murine α(1,3)galactosyltransferase [α(1,3)GT] enzyme adds α(1,3)galactosyl epitopes (αgal) onto glycoproteins and glycolipids. Pre-existing human antibody can bind these epitopes and fix complement resulting in the direct lysis of the murine cells. Our data suggests that an innocent bystander effect then occurs which induces the destruction of adjacent cancer cells and possibly stimulates anti-tumor immunity. Though it is believed the bystander effect is responsible for destruction of the tumor cells, a different or several mechanisms may be responsible.
- The present invention seeks to shift the current understanding of published trials stating that HSVtk and ganciclovir (GCV) gene therapy is efficacious for the treatment of solid tumors in adults. These trials were designed with the idea that murine VPC xenografts would provide the production of retroviral vectors within solid tumors and efficiently transfer the HSVtk gene. This gene transfer was then expected to sensitize solid tumors to GCV. Furthermore, a bystander effect caused by metabolic cooperation was to enhance the effect, so that if only a small portion of the tumor was transduced with HSVtk, then the entire tumor could be destroyed. In cell culture and animal models of HSVtk and GCV therapy, 10-20% of the tumor needed to express the HSVtk gene to obtain complete response. Moolten, F. L., Cancer Res. 46, 5276-5281 (1986); Culver, K. W. et al., Science 256, 1550-1552 (1992); Link, C. J., Kolb, E. & Muldoon, R.,
Hybridoma 14, 143-147 (1995). The implantation of VPC is superior to implanting HSVtk pre-transduced cells alone to increase the delivery of the HSVtk gene. However, in animal models, this approach is often not successful even when 50% of the cells are pretransduced with HSVtk for a variety of human tumor xenografts (Link, unpublished observations). In a preclinical model of intraperitoneal colon adenocarcinoma treated with LTKOSN VPC, a 50% transduction frequency was required to cure 50% of the animals of syngeneic MC38 tumor grafts. Link, C. J., Kolb, E. & Muldoon, R., Hybridoma. 14, 143-147 (1995). Therefore, high level gene transfer is required in these model systems, and it is very unlikely that the conditions for in vivo gene transfer in humans would be more favorable. Specifically, these trials have made claims that are overly simplistic and presume an effect of HSVtk gene and GCV on tumors. These agents have now been expanded into larger trials in the United States and abroad. Further scientific understanding of the basic human immune response to these murine vector producer cells should aid in the further development of VPC technology and provide insight into this potentially important approach to cancer treatment. - A Phase I trial of 10 patients with recurrent ovarian or fallopian tube cancers was conducted using the xenotransplantation of murine retroviral LTKOSN.1 VPC for in vivo transfer of the HSVtk gene. All patients had failed prior therapy with paclitaxel and either cisplatin or carboplatin. LTKOSN.1 VPC were infused into the peritoneal cavity in doses from 1×106 to 1×108 cell/kg. After 4 weeks, patients were treated with GCV for 2 weeks. Viable VPC were recovered from peritoneal washes on day +3 and/or day +7 after infusion at the two highest dose levels. The recovered VPC were still able to produce high titer LTKOSN retroviral vector. VPC were detectable by PCR up to day +7, but at day +14 none were detected. Tumor tissue obtained on day +14 prior to first GCV injection were positive for the HSVtk gene by PCR. Four of ten evaluable patients demonstrated some evidence of anti-tumor response. One patient had a complete resolution of a 2 cm mass on CT scan and a 70% reduction of CA125. Of the remaining 3, first patient had a partial, second patient a minor, and the third patient showed a mixed response to the treatment. The patient with the mixed response demonstrated significant resolution of malignant ascites prior to GCV infusion, but developed a malignant pleural effusion. Quantitative PCR analysis demonstrated less than 1% gene transfer into intraperitoneal tumor biopsies prior to GCV administration. All patients were treated as outpatients.
- It is surprising that anti-tumor responses were observed although only low level gene transfer was noted. These data suggest the process of hyperacute rejection associated with the administration of murine VPC has an adverse effect on the intraperitoneal tumor.
- Since it is believed that the gene transfer was not necessary to the anti-tumor reaction, it is believed that any xenogeneic cells which will activate the hyperacute rejection will be effective in the invention. One of ordinary skill in the art would be able to determine which cells other than murine cells which will be safe and effective. There are many commercial and academic sources of cell lines. Additionally, one of ordinary skill would be able to develop cells lines to use in the present invention.
- The Examples show that the xenogeneic cells were infused into the peritoneal cavity in the vicinity of the tumor using a catheter. One of ordinary skill would be able to determine other methods of presenting the xenogeneic cells to the body in order to induce the hyperacute rejection and bystander effect.
- The dose levels of xenogeneic cells that have been used are shown in the Examples. One of ordinary skill would be able to determine a dose level appropriate for the tumor and the patient which is both safe and effective.
- The prior art method of gene expression and activation of an added prodrug may be effective used concurrently with the treatment of the present invention (hyperacute rejection/bystander effect), this gene therapy/prodrug method may be used as an add-on therapy. Additionally, since it appears that the physiology of the tumor changes after induction of the hyperacute rejection and the bystander effect, chemotherapy appears to be effective after the treatment of the present invention where the chemotherapy was achieving little, if any, results prior to this new treatment. One of ordinary skill would be able to determine additional treatments which will work prior to, in conjunction with, or subsequent to the present treatment.
- The vector present in the VPC that was used in the present invention was LTKOSN. LTKOSN is a retroviral vector derived from the Moloney murine leukemia virus (MoMLV). The vector LTKOSN contains a Herpes Simplex type I thymidine kinase (HSVtk) gene cDNA that is transcribed from the viral long terminal repeat (LTR) and a bacterial neomycin resistance (neor) gene transcribed from an internal SV40 (simian virus 40) early promoter (LTR-HSVtk-SV-neor-LTR) in the LXSN backbone. This vector has been modified for increased safety by alteration of the gag start codon to a stop codon, and by elimination of viral sequences to minimize the potential for the development of replication-competent virus from producer cells which contain the vector.
- The present invention was used to treat ovarian and fallopian cancer which are solid tumors. One of ordinary skill would be able to determine other tumors which will respond to the treatment of the present invention.
- The data from the Phase I trial of the present approach did not support the published conclusions of researchers (e.g., Ram, Z. et al., Nature Med. 3 1354-1361 (1997); Klatzman, D. et al., Human Gene Ther. 9, 2585-2594 (1998)). The current trial was designed to determine if antitumor responses observed in earlier trials, often attributed by other investigators to HSVtk enzyme activation of GCV, is correct. The current paradigm theorized that HSVtk gene activation of GCV leads to a bystander effect that accounts for observed antitumor responses. The results of this investigation may overturn the current paradigm accepted by investigators in molecular medicine. This finding leads to better scientific and clinical investigations if VPC is the delivery vehicle. The current investigation also provides insight into novel antitumor mechanism (hyperacute rejection) and might be further developed and exploited to benefit cancer patients.
- The initial interest in hyperacute rejection resulted from studies of destruction of murine vector producer cells (VPC) by peritoneal fluid. VPC have been proposed for in vivo gene delivery as a potential improvement over retroviral particles alone to increase the transduction efficiency in tumor models. Short, M. P., Choi, B. C., Lee, J. K., Malick, A., Breakefield, X. O., and Martuza, R. L., Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line J. Neurosci. Res. 27, 427-439 (1990). The human serum mediated destruction of murine VPC was immediate. The results indicated that substantial VPC killing occurred after their exposure to peritoneal fluid. It was demonstrated that heparin, enoxaparin, or sCR1 could specifically block lysis of murine cells by human serum. Link, C. J., Levy, J. P., Seregina, T., Atchinson, R. & Moorman, D., Cancer Gene Therapy (eds Mazarakis, H. & Swart, S. J.) 135-152 (IBC Library Series, London, United Kingdom, 1997). SCR1 is a soluble form of
complement receptor 1 that binds activated complement and prevents the attack complex from damaging the cell membrane. - A Phase I clinical trial was completed with 10 patients with recurrent ovarian or fallopian tube cancer. This study was conducted using the xenotransplantation of murine retroviral LTKOSN.1 VPC for in vivo transfer of the HSVtk gene. All patients had failed prior therapy with paclitaxel and either cisplatin or carboplatin. All patients were treated as outpatients. LTKOSN.1 VPC were infused intraperitoneally with doses from 1×106 to 1×108 cell/kg. After 2 weeks, patients were treated for two weeks with ganciclovir (GCV). The data is detailed in Tables 1 and 2.
TABLE 1 Clinical Outcome in Ovarian Cancer Patients Treated with LTKOSN.1 VPC. Signs Gene Age/ Dose Dose and transfer Patient Stage Tumor level (VPC) symptoms observed Result Comments 1 64 Ovarian 1 6 million abd. Not Partial Local tumor IIIC pain, tested response necrosis on nausea histopathology 2 47 Ovarian 1 57 million abd. No Mixed Resolved IIIC pain, response ascites before nausea GCV Rx 3 59 Ovarian 1 56 million abd. No Progressive Deceased 15 IIIC pain disease mos. after treatment 4 51 Ovarian 2 680 million abd. Yes Progressive Deceased 5 IIIC pain, disease mos. after fever, treatment nausea, vomiting 5 62 Ovarian 2 700 million abd. Not Progressive Deceased 6 IIIC pain, tested disease mos. after fever, treatment nausea 6 66 Fallopian 2 840 million abd. Yes Minimal Deceased 8 IIIC pain, response mos. after fever treatment 7 73 IV Ovarian 3 7 billion abd. No Progressive Receiving pain disease chemotherapy 8 60 Ovarian 3 6.3 billion abd. No Mass lesion CT scan still IIIC pain (2 cm) without regressed, disease 21CA125 mos. later; decreased ↑CA125 70% 9 63 Ovarian 3 6.2 billion abd. yes Progressive Deceased 3 IIIC pain, disease mos. after nausea, treatment vomiting 10 52 Ovarian 3 5.7 billion rash, pending Progressive Receiving IIIC abd. disease chemotherapy pain -
TABLE 2 VPC Survival in Patient's Peritoneal Cavity and In Vivo HSVtk Gene Transfer in Patients Treated with Escalated Doses of LTKOSN.1 Retroviral VPC. Day 14 (pre- Patient number Cell Day 3 Day 7 GCV treatment) (VPC dose) source HSVtk env VPC (cfu/ml) HSVtk env VPC (cfu/ml) HSVtk env 1 PW − − − − − − − − (1 × 106 cells/kg) TB NA NA NA NA NA NA 2 PW − − − − − − − − (1 × 106 cells/kg) TB NA NA NA NA NA NA 3 PW − − − − − − − − (1 × 106 cells/kg) TB NA NA NA NA NA NA 4 PW + + − + + − − − (10 × 106 cells/kg) TB NA NA NA NA NA NA + − 6 PW + + 1.5 × 106 + + 1.3 × 106 − ND (10 × 106 cells/kg) TB NA NA NA NA NA NA + ND 7 PW + + − + + − − − (100 × 106 cells/kg) TB NA NA NA NA NA NA − − 8 PW + + − + + − − − (100 × 106 cells/kg) TB NA NA NA NA NA NA − − 9 PW + + >1 × 106 + − − + − (100 × 106 cells/kg) TB NA NA NA NA NA NA + − 10 PW + Pending − + Pending − + Pending (100 × 106 cells/kg) TB NA NA NA NA NA NA + Pending
PW: peritoneal wash;
TB: tumor biopsy during laparoscopy;
−: negative;
+: positive;
NA—not applicable;
ND—not done
Most patients developed some abdominal pain consistent with peritoneal irritation that lasted for up to 7 days, and 3 patients had low grade fever. One patient exhibitedgrade 2 nausea and vomiting, otherwise,only grade 1 toxicities were observed. Four of ten evaluable patients demonstrated some evidence of an antitumor response. One patient had the complete resolution of a 2 cm mass on CT scan and a 70% reduction of CA125. Of the remaining three, one patient had a partial, the second patient a minor, and the third patient showed a mixed response to the treatment. The patient with the mixed response demonstrated significant resolution of malignant ascites prior to GCV infusion, but developed a malignant pleural effusion. Tumor tissues obtained on day +14 prior to GCV were positive for the HSVtk gene by PCR in several patients. Quantitative PCR analysis demonstrated less than 1% gene transfer into intraperitoneal tumor biopsies prior to GCV administration.FIG. 1 shows the results of PCR analysis of peritoneal washes and biopsies conducted onpatient 4. The demonstration of tumor regression with only low level gene transfer (<1%) suggests that hyperacute rejection of the murine cells might inhibit the cancer by an innocent bystander effect such as that described for red blood cells (RBC) in penicillin antigen-antibody complex-mediated hemolytic anemia. Schwartz, R. S., Silberstein, L. E. & Berkman, E. M. Autoimmune hemolytic anemia. In Hemotology Basic Principles and Practice, 2nd ed. (eds Hoffman, R. et al.) 723-724 (Churchill Livingstone, N.Y., 1995). The penicillin antigen-antibody complexes adhere to the RBC membrane and activate complement against the RBC. The agal and anti-αgal antigen-antibody may adhere to tumor cells and possibly activate complement and injure the tumor cells. Viable LTKOSN.1 murine VPC were recovered from peritoneal wash samples of patients on day +3 and/or day +7 after infusion at the two highest dose levels. The recovered VPC cultures were G418 resistant, and their supernatants contained high titers of LTKOSN retroviral vector similar to those produced by LTKOSN.1 VPC used for infusion into patients (1-1.5×105 cfu/ml). VPC were detectable by PCR up to day +7, but at day +14 none were detected (FIG. 1 ) - Replication competent retrovirus (RCR)S+L− assays were conducted on peripheral blood lymphocytes (PBL) of patients. Cells were co-cultured with Mus dunni cells for two weeks (four passages). After two weeks, supernatants were collected and centrifuged. The supernatant was then placed on PG-4 cells (40 to 60% confluent) for two hours. The supernatant was removed and D10 (DMEM, 10% fetal bovine serum, L-glutamine) added. After four to seven days, PG-4 cells were observed for development of foci. MMLV 4070A was used as the positive control, and Mus dunni cells alone were used as the negative control. No RCR was present in PBL samples obtained up to one year after VPC infusion as detected in co-cultivation with Mus dunni followed by S+L-assay.
- Genomic DNA was isolated from 3 ml of whole blood using the Genomic DNA Purification Kit (Promega or Sigma). Tumors were digested by mincing the tissue and adding tumor lysis solution (2 mg/ml Collagenase, Type II; 0.2 mg/ml DNAaseI; 2.1 μg/ml Ilyaluronidase, Type V). The tumor was dissociated on a slow rocker at RT for 1 hour, and cells were collected by filtering through a nylon mesh. The peritoneal wash samples were centrifuged to collect all the cells, and DNA was isolated using the Genomic DNA Isolation Kit (Sigma). Isolation of genomic DNA from A375 LTKOSN.1 cells diluted with A375 NV cells was used to create 10−2, 10−3, 10−4, and 10−5 cell dilutions for PCR controls.
- MLVENV-F (5′-ACCTGGAGAGTCACCAACC-3′) SEQ ID NO:1 and MLVENV-R (5′-TACTITGGAGAGGTCGTAGC-3′) SEQ ID NO:2 were designed to amplify a 411 bp fragment of the env gene. The PCR reaction was 3 min. at 94° C., followed by 30 cycles of 94° C. for 20 seconds, 68° C. for 1 minute, and 72° C. for 1 minute, with a final extension of 10 minutes at 72° C. The reaction mix was 500 ng of genomic DNA (sample), 25 pmoles of each primer, 1×PCR buffer, 0.2 mM dNTPs, 1.25 MM MgCl2, and 1.25 U Taq. A375 NV cells and a sample containing no genomic DNA were used as negative controls. 100 fg of pPAM3 was used as a positive control for each sample. For the lymphocyte samples, 500 ng of each A375 LTKOSN.1 dilution of genomic DNA (1×10−4 and 5×10−4) was used as additional controls. PCR product from blood lymphocytes and controls were transferred to membrane using a slot blot. The env probe was labeled with (32P)dCTP by the random priming technique (Boehringer Mannheim). The blots were hybridized overnight at 42° C. in Hybridisol (Oncor) and washed. No env gene sequence was detected by PCR in PBL samples obtained up to one year after VPC infusion.
- PCR was Performed to Detect HSVtk Gene in PBL and Tumor Biopsy Samples
- PCR primers (
JMTKO1 5′ TAT AGA CGG TCCTCA CGG GAT 3′ SEQ ID NO:3 andJMTKO3 5′ TCA TGC TGC CCATAA GGT AT 3′) SEQ ID NO:4 were designed to amplify a 388 bp fragment of the TK gene. The reaction mix contained 500 ng of genomic DNA sample. A375 NV cells and a sample containing no genomic DNA was used as negative controls. 100 fg of pLTKOSN.1 was used as a positive control for each sample. For the lymphocyte samples, 500 ng of each A375 LTKOSN.1 dilution of genomic DNA (10−2, 10−3, 10−4, and 10−5) was used as additional controls. 500 ng of 10−3 and 10−4 dilutions of A375 LTKOSN.1 genomic DNA were used as controls for the tumor and peritoneal wash cells. PCR product from blood lymphocytes and controls were transferred to membrane using a slot blot. A TK probe was labeled with (32P)dCTP by the random priming technique (Boehringer Mannheim). PCR products from peritoneal wash and tumor samples were run out on 1.5% TBE gels and Southern transferred onto nylon membrane following manufacturer's instructions. No HSVtk gene transfer into PBL from patient blood samples up to 3 months after VPC infusion were detected by PCR in any patient. - Patients' serial blood samples were drawn before VPC infusions and then weekly thereafter. These samples were evaluated by ELISA assay for anti-αgal Ab titers as previously described (
FIG. 2 ). Galili, U., Tibell, A., Samuelsson, B., Rydberg, L. & Groth, C. G. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 59, 1549-56 (1995). Plates (96-well) were coated with 1 μg α-gal-BSA per well. Serial dilutions of patient serum samples were used as the primary antibody, and horseradish peroxidase conjugates of anti-human IgG served as the secondary antibody. It was expected that patients who received murine cell xenografts would generate increases in anti-αgal titers. Previously, diabetic patients grafted with fetal porcine islet cells had been noted to develop an increase in anti-αgal titers (8 to 64-fold), while total immunoglobulin concentration was unchanged. Galili, U., Tibell, A., Samuelsson, B., Rydberg, L. & Groth, C. G., Transplantation 59, 1549-56 (1995). Thus, the increase in anti-αgal titer was the result of a specific immune response against αgal epitopes on the xenograft. In the first 3 patients treated with 1×106 VPC/kg (range 54-57×106 VPC), no increases in anti-αgal titers were seen. However, strong and significant response to the αgal antigen was observed at the higher doses.Patients 4 through 9 treated at 10-100×106 VPC/kg dose had 2-fold to 256-fold increases in anti-αgal titers by ELISA. No significant difference in concentration of IgG and IgM was found in peripheral blood serum samples obtained prior and onday 14 following murine VPC infusion (data not shown). Thus, the Ab response is a specific anti-αgal immune response. This might be another way to enhance the immune effects against the tumor and break tolerance. Results from this Phase I clinical trial of LTKOSN.1 VPC for women with recurrent ovarian cancer suggest a possible role for hyperacute rejection in anti-tumor responses in humans. - Aliquots of 1×106 LTKOSN.1 VPC, with viability not less than 95%, were suspended in incubation medium containing 90% of patient serum and 10% of DMEM (Gibco). The cell suspension was incubated at 37° C. for one hour, and cell viability was assessed using trypan blue exclusion. Patient serum inactivated for 30 minutes at 56° C. served as a negative control for complement-dependent murine VPC destruction. Human A375 melanoma cells (1×106/aliquot) served as a control for species-specific anti-αgal antibody-mediated cytotoxicity of patients' sera. Serum samples were obtained prior to and 7 and 14 days post murine VPC infusion. The data demonstrated that serum from 7 out of 9 patients killed nearly 100% of murine VPC in this assay (
FIG. 3 ). By day 28 after the infusion of VPC, all patients' sera killed 100% of murine VPC. Viability of A375 cells was not affected by exposure to human serum. Thus, in all patients, sera alone could destroy murine VPC. These findings also support the contention that bleeding during neurosurgical procedures would kill murine VPC rapidly. - Peritoneal washes were performed during patient evaluation and on
days FIG. 4 . Interestingly, the peritoneal fluid from only one patient initially killed more than 50′ of the VPC in this assay. Thus, the pre-existing serum killing ability in the patients (FIG. 3 ) did not translate into peritoneal fluid that would kill VPC under these ex vivo experimental conditions. However, over the 30 days after murine VPC infusion, the peritoneal fluid was able to mediate high level VPC killing. We have been able to show that the anti-agal titer increases in the peritoneal cavity after VPC infusion (data not shown). Little detectable IgG was present in the peritoneal fluid in most patients before the xenotransplant; however, the total IgG in the peritoneal cavity increased dramatically in four of six patients tested. This suggests that the anti-αgal Ab response to murine cells altered the physiology of the peritoneal cavity. These findings correlate with the timing of the observed antitumor responses. For example,patient # 8 who manifested the best and most durable anti-tumor response observed had a high induced serum titer of anti-αgal Ab (32-fold increase) and a rapid up-slope in the ability of her peritoneal fluid to kill murine VPC in the ex vivo assay. These data support a correlation between anti-αgal immunity and tumor response, but in this Phase I trial GCV was administered 14 days after VPC, and this temporal overlap makes conclusions about causation difficult. The proposed trial design of waiting 4 weeks after VPC infusion to treat with GCV may allow these effects to be separated. Changes in the peritoneal cavity may alter the ability of the immune system to detect these tumors. - Peritoneal wash samples were centrifuged at 250×g, and the cell pellets were resuspended in DMEM supplemented with 10% FBS (Gibco) and aliquoted. One mg/ml of G418 (Gibco) was added to one aliquot, and cells were incubated at 37° C., 5% CO2. Cells in samples containing VPC reached confluency in approximately 10 days after cell culture initiation. Cells were cultured in medium containing one mg/ml G418 for two additional weeks, then the supernatant was used to infect IGROV human ovarian carcinoma cells in standard vector titration assay as established at our Institute. The data on the recovered VPC is shown in Table 2 and clearly demonstrates that high titer VPC can be recovered up to 7 days after intraperitoneal infusions.
- Anti-Fetal Bovine Serum Response
- The humoral immune response to fetal bovine serum (FBS) was also tested (
FIG. 5 ). ELISA for anti-FBS was performed in Nuclon 96-well plates were coated with BSA by filling wells with 100 μl of 5% BSA in PBS and incubating at 4° C. overnight. The plate was washed four times with PBS, and 150 μl of blocking buffer (1% dry milk; 0.1% SDS) was added and incubated at room temperature for one hour. Primary antibody (100 μl diluted patient serum (1:50) samples followed by serial dilution) was added following 4 washes and incubated for one hour. After four washes, 150 μl of blocking buffer was added, and the plate was incubated two hours. The secondary horseradish peroxidase-conjugated antibody [100 μl of antibody; 1/40,000 dilution of goat anti-human (Pierce) for patient samples; 1/15,000 dilution of goat anti-bovine (Kirkegaard & Perry) for positive control] was added and incubated for one hour. Following four washes, 100 μl of room temperature TMB (Sigma) substrate was added and color was allowed to develop for 15 minutes. The reaction was stopped by adding 100 μl of 1 M H2SO4. Absorbance values were read at 450 nm on an ELISA plate reader. Only 3 patients developed anti-FBS Ab (out of 9 tested). - Human Tumor Cell Clones Susceptible to Serum Killing Express αgal
- To demonstrate the significance of α(1,3)GT, our group has previously demonstrated that the retroviral transfer of α(1,3)GT into tumor cells can induce sensitivity to normal human serum. Human tumors are not sensitive to lysis by autologous human serum. A truncated version of the murine α(1,3)GT enzyme was cloned into the LNCX retroviral vector backbone. Larsen, R. D., Rajan, V. P., Ruff, M. M., Kukowska-Latallo, J., Cummings, R. D., and Lowe, J. B. Isolation of a cDNA encoding a murine UDPgalactose:beta-D-galactosyl-1,4-N-acetyl-D-glucosaminide alpha-1,3-galactosyltransferase: expression cloning by gene transfer Proc. Natl. Acad. Sci. U.S.A. 86(21), 8227-31 (1989); Miller, A. D. & Buttimore, C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production Molec. Cell Biol. 6, 2895-2902 (1986). This eukaryotic expression vector was transfected into human A375 melanoma tumor cells that were then exposed to human serum. Many A375 subclones were obtained, and data for three representative examples are presented. Clones A375αG.7 and A375αG.8 showed significant sensitivity to serum killing while clone A375αG.11 did not (Table 3).
TABLE 3 Effect of human serum on A385αG cells. Human serum Human Human Heat αgal serum serum + sCR1 inactivated expression Cell line % viable % viable % viable by FACS A375 98.7 Not done 96.9 − A375αG.7 2.6 92.0 93.9 + A375αG.8 11.1 91.6 95.5 + A375αG.11 96.2 Not done Not done −
Incubation with sCR1 prevented cell killing by serum. The sensitive clones A375αG.7 and A375αG.8 expressed αgal by FACS analysis, while clone A375αG.11 did not exhibit the epitope. These data show that the presentation of αgal alone on human tumor cells induces sensitivity to human serum. - Investigators have demonstrated that certain types of lectins bind specifically to agal on glycoproteins or glycolipids. Wood, C., Kabat, E. A., Murphy, L. A. & Goldstein, I. J. Immunochemical studies on the combining site of two isolectins A4 and B4 isolated from Bandeirea simpliciflia Arch. Biochem. Biophys. 198, 1-11 (1979). This method was used to quantify the amount of αgal present on cells using Griffonia simplicifolia isolectin B4 (Vector Laboratories, Burlingame, Calif.) and analyzed by COULTER FACS analyzer. The presence of agal epitopes correlated with sensitivity to human serum for the A375αgal clones. The next step in acquiring evidence needed to pursue this strategy was to demonstrate in vivo differences in an animal model. This presented a problem since murine cells contain an intact a(1,3)GT gene. So, we injected original A375 cells and A375 cells expressing agal into athymic nude mice after brief (30 min) exposure to human serum ex vivo. Animals were monitored for tumor growth for up to 28 days. Only animals injected with A375αG.7 cells exposed to human serum and irradiated A375 cells (positive control) were tumor free. The α(1,3)GT gene can also sensitize cells to normal human serum when transferred by a Herpes simplex vector into ovarian or colon carcinoma cells.
- One striking finding in patents was the development of eosinophilia in the peripheral blood and the peritoneal cavity during time of xenograft rejection (
FIG. 6 ). The peripheral blood eosinophil count increased on average by 87% byday 14 after murine cells administration. Intraperitoneal washing cell counts demonstrated a mean of 15% (5-28%) and 13% (1-33%) eosinophils ondays - The Phase II trial will involve 43 adult women with recurrent or refractory ovarian, fallopian, or peritoneal carcinoma, will be evaluated for the extent and location(s) of their disease before being entered into the study. Patients will have a CT scan and laparotomy or laparoscopy with biopsy to confirm the diagnosis. During laparoscopy, eligible patients will have a peritoneal dialysis catheter placed. HSVtk VPC will be infused into the peritoneal space over 15-60 minutes in a total volume of one to two liters of plasmalyte. Four weeks later, GCV will be administered over one hour at 5 mg/kg/dose IV b.i.d. for 14 days. Patients may receive up to three cycles of therapy if no tumor regression is observed. After the completion of therapy, patients who continue to show evidence of response will be followed every three months for the first year.
- Having described the invention with reference to particular compositions, theories of effectiveness, and the like, it will be apparent to those of skill in the art that it is not intended that the invention be limited by such illustrative embodiments or mechanisms, and that modifications can be made without departing from the scope or spirit of the invention, as defined by the appended claims. It is intended that all such obvious modifications and variations be included within the scope of the present invention as defined in the appended claims. The claims are meant to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates to the contrary.
Claims (33)
1. A method for treating a solid tumor in an αGal(−) mammal, having anti-αGal antibodies, said method comprising:
administering to said mammal at or near said tumor, an effective amount of cells having an α(1,3) galactosyl epitope to activate a local hyperacute rejection, wherein said cells are other than vector producing cells.
2. The method of claim 1 , wherein the tumor is in the peritoneal cavity.
3. The method of claim 1 where the αGal(−) mammal is a human.
4. The method of claim 1 where the cells having an aGal epitope are of xenogeneic origin, obtained from an αGal(+) mammal.
5. The method of claim 4 where said mammal is of murine origin.
6. The method of claim 4 where said cells are from murine origin.
7. The method of claim 1 where αGal(+) cells are human cells obtained by introduction of a polynucleotide sequence expressing the alpha(1,3) galactosyltransferase gene.
8. The method of claim 7 where the alpha(1,3) galactosyltransferase gene is from murine origin
9. A method for treating a solid tumor in a human, the method comprising:
administering at or near said tumor an effective amount of cells having an α(1,3) galactosyl epitope, said cells being characterized in that they do not have a functional retroviral gag gene wherein said cells activate a hyperacute rejection response thereby inhibiting the growth of a tumor in said human.
10. The method of claim 9 , wherein the tumor is in the peritoneal cavity.
11. The method of claim 9 where the cells having aGal epitopes are of xenogeneic origin, obtained from an αGal(+) mammal.
12. The method of claim 11 where such mammal is of murine origin.
13. The method of claim 11 where such cells are from murine origin.
14. The method of claim 9 where αGal(+) cells are human cells obtained by introduction of a polynucleotide sequence expressing the alpha(1,3) galactosyltransferase gene.
15. The method of claim 14 where the alpha(1,3) galactosyltransferase gene is from murine origin
16. A method for inhibiting the growth of a solid tumor in a human having anti-αGal antibodies, the method comprising:
delivering into or near the tumor an effective amount of a xenogeneic cell that expresses an α (1,3) galactosyl epitope and that does not produce retroviral proteins thereby causing a local hyperacute rejection response against said xenogeneic cell and a bystander immune reaction against the tumor thereby inhibiting the growth of the tumor in the subject.
17. A method of inhibiting the growth of a solid tumor in a human subject, the method comprising:
administering to said subject into or near the tumor an effective amount of xenogeneic cells containing an α(1,3)galactosyl epitope and which do not produce retroviral virions, in order to activate a hyperacute rejection response thereby inhibiting the growth of said tumor.
18. A method for activating an immune response against a solid tumor in a human subject, the method comprising:
administering to said subject into or near the tumor an effective amount of xenogeneic cells containing an α(1,3)galactosyl epitope and which do not produce retroviral virions, without subsequent administration of ganciclovir, where said xenogeneic cells activate an immune response against said tumor.
19. A method for inhibiting growth of a solid tumor in an animal with pre-existing anti-alpha Gal antibodies comprising:
administering to said animal, into or near the tumor, an effective amount of xenogeneic cells containing an α (1,3) galactosyl epitope and which do not contain a tumor specific antigen specific for said solid tumor, to generate a localized hyperacute rejection response near to said solid tumor to inhibit the growth of said tumor.
20. A method for eliciting an immune response against tumor specific antigens which are present within a solid tumor in an animal with pre-existing anti-alpha Gal antibodies comprising:
administering to said animal, into or near the tumor, an effective amount of xenogeneic cells containing an α (1,3) galactosyl epitope and which do not generate retroviral virions, to create a localized hyperacute rejection response near said solid tumor and a concomitant immune response against tumor specific antigens within said solid tumor thereby inhibiting the growth of said tumor
21. The method of claim 20 wherein said xenogeneic cells do not contain a tumor specific antigen for said solid tumor in said animal.
22. A method for eliciting an immune response against tumor specific antigens which are present within a solid tumor in an animal with pre-existing anti-alpha Gal antibodies comprising:
administering to said animal an effective amount of xenogeneic cells containing an α(1,3) galactosyl epitope and which do not contain said tumor specific antigen for said solid tumor and do not generate retroviral particles, to create a localized hyperacute rejection response near said solid tumor thereby inhibiting the growth of said tumor
23. A pharmaceutical composition to inhibit the growth of a solid tumor in a human subject, said composition comprising αGal(+) cells which do not contain a tumor specific antigen present in said tumor.
24. The composition of claim 23 where such cells are αGal(+) cells of murine origin.
25. The composition of claim 23 where such cells are human cells obtained by introduction of a polynucleotide sequence directing the expression of an alpha(1,3) galactosyltransferase gene.
26. The composition of claim 25 where such alpha(1,3) galactosyltransferase gene is of murine origin.
27. The composition of claim 26 wherein said cells are inactivated.
28. The composition of claim 23 wherein said αGal(+) cells are inactivated by ultraviolet, gamma or X irradiation.
29. The composition of claim 23 wherein said cells do not contain a retroviral nucleotide sequence.
30. The composition of claim 23 wherein said cells do not contain a functional gag gene.
31. The method of claim 23 wherein said cells do not produce retroviral proteins.
32. The method of claim 23 wherein said cells are other than vector producing cells.
33. A method for eliciting an immune response against tumor specific antigens which are present within a solid tumor in an animal with pre-existing anti-alpha Gal antibodies comprising:
administering to said animal an effective amount of xenogeneic cells containing an α (1,3) galactosyl epitope and which do not contain predetermined tumor specific antigens for said solid tumor and do not generate retroviral particles, to create a localized hyperacute rejection response near said solid tumor and an immune response to said tumor
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/221,515 US20060034812A1 (en) | 1999-06-08 | 2005-09-08 | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13803899P | 1999-06-08 | 1999-06-08 | |
US09/589,255 US7005126B1 (en) | 1999-06-08 | 2000-06-07 | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
US11/221,515 US20060034812A1 (en) | 1999-06-08 | 2005-09-08 | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/589,255 Continuation US7005126B1 (en) | 1999-06-08 | 2000-06-07 | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060034812A1 true US20060034812A1 (en) | 2006-02-16 |
Family
ID=35922697
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/589,255 Expired - Fee Related US7005126B1 (en) | 1999-06-08 | 2000-06-07 | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
US11/221,515 Abandoned US20060034812A1 (en) | 1999-06-08 | 2005-09-08 | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/589,255 Expired - Fee Related US7005126B1 (en) | 1999-06-08 | 2000-06-07 | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect |
Country Status (1)
Country | Link |
---|---|
US (2) | US7005126B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018067813A1 (en) | 2016-10-05 | 2018-04-12 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and systems for augmenting immune system responses |
US12016973B2 (en) * | 2017-10-05 | 2024-06-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and systems for augmenting immune system responses |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1756568A (en) | 2002-10-09 | 2006-04-05 | 衣阿华中央卫生系统 | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
US20050201993A1 (en) * | 2002-10-09 | 2005-09-15 | Link Charles J.Jr. | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
US7998486B2 (en) | 2006-10-25 | 2011-08-16 | Newlink Genetics Corporation | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes |
US7988723B2 (en) | 2007-08-02 | 2011-08-02 | Flexible Stenting Solutions, Inc. | Flexible stent |
US9149376B2 (en) | 2008-10-06 | 2015-10-06 | Cordis Corporation | Reconstrainable stent delivery system |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869035A (en) * | 1996-11-13 | 1999-02-09 | Human Gene Therapy Research Institute | Methods and compositions for inducing complement destruction of tissue |
US5879675A (en) * | 1994-03-15 | 1999-03-09 | Medical College Of Pennsylvania And Hahnemann University | Compositions and methods for vaccines comprising α-galactosyl epitopes |
US6045789A (en) * | 1992-05-01 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bystander effect tumoricidal therapy by expressing an HSV-tk gene |
US20040234511A1 (en) * | 2001-08-28 | 2004-11-25 | Rush University Medical Center | Immune tolerance to predetermined antigens |
-
2000
- 2000-06-07 US US09/589,255 patent/US7005126B1/en not_active Expired - Fee Related
-
2005
- 2005-09-08 US US11/221,515 patent/US20060034812A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6045789A (en) * | 1992-05-01 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bystander effect tumoricidal therapy by expressing an HSV-tk gene |
US5879675A (en) * | 1994-03-15 | 1999-03-09 | Medical College Of Pennsylvania And Hahnemann University | Compositions and methods for vaccines comprising α-galactosyl epitopes |
US6361775B1 (en) * | 1994-03-15 | 2002-03-26 | Medical College Of Pennsylvania | Compositions and methods for vaccines comprising α-galactosyl epitopes |
US5869035A (en) * | 1996-11-13 | 1999-02-09 | Human Gene Therapy Research Institute | Methods and compositions for inducing complement destruction of tissue |
US20040234511A1 (en) * | 2001-08-28 | 2004-11-25 | Rush University Medical Center | Immune tolerance to predetermined antigens |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018067813A1 (en) | 2016-10-05 | 2018-04-12 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and systems for augmenting immune system responses |
EP3522850A4 (en) * | 2016-10-05 | 2020-05-27 | Arizona Board of Regents on behalf of the University of Arizona | Methods and systems for augmenting immune system responses |
US12016973B2 (en) * | 2017-10-05 | 2024-06-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and systems for augmenting immune system responses |
Also Published As
Publication number | Publication date |
---|---|
US7005126B1 (en) | 2006-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2117303C (en) | Anti-cancer immunotherapeutic vector constructs | |
Uckert et al. | Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo | |
US6110458A (en) | Cancer therapy utilizing ex vivo gene transduction | |
EP0551401B2 (en) | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity | |
AU675948B2 (en) | Bystander effect tumoricidal therapy | |
Garnett et al. | TRICOM vector based cancer vaccines | |
ES2262242T3 (en) | USE OF CLASS II MHC LINKS AS ADVANCES FOR VACCINATION AND LAG-3 IN CANCER TREATMENT. | |
US20060034812A1 (en) | Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect | |
JP2002515734A (en) | Immunostimulation mediated by genetically modified dendritic cells | |
JPH09503740A (en) | Inhibition of selected tumor growth by recombinant viral vectors | |
JPH06502399A (en) | Pharmaceutical composition for the treatment or prevention of malignant tumors | |
Zwacka et al. | Gene therapy for colon cancer | |
EA015510B1 (en) | Method for enhancing the amount of mononuclear cells in a subject suffering from cancer, and pharmaceutical combination used therefor | |
Moon et al. | Current status of experimental therapeutics for prostate cancer | |
JPH09504518A (en) | Treatment of tumors by gene transfer of tumor cells with genes encoding negative selectable markers and cytokines | |
Metharom et al. | Gene transfer to dendritic cells induced a protective immunity against melanoma | |
JP4014628B2 (en) | New grafts and new vectors for the treatment of acquired diseases | |
JP4423508B2 (en) | Cancer gene therapy drug | |
Bubenik et al. | Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines | |
Gómez-Navarro et al. | Gene therapy: ovarian carcinoma as the paradigm | |
Dorigo et al. | Gene therapy for ovarian cancer: development of novel treatment strategies | |
LINK JR et al. | Preliminary in vitro efficacy and toxicities studies of the herpes simplex thymidine kinase gene system for the treatment of breast cancer | |
ES2236735T3 (en) | PROCEDURE FOR EXTENSION OF EXPRESSION OF A GENE OF INTEREST USING SOLUBLE CTLA4 MOLECULES. | |
Culver et al. | Gene therapy for brain tumors | |
Gdor et al. | Gene therpay for prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |